Biopharma start-up co-founded by TCD professor raises $30m
Sitryx’s co-founders include Luke O’Neill, prof of biochemistry at Trinity college
Dr O’Neill, one of Sitryx’s founders also co-founded Opsona Therapeutics
The Oxford-headquartered company, which was only established earlier this year, is focused on regulating cell metabolism to develop disease-modifying therapeutics in immune-oncology and immunoinflammation.
Sitryx was co-founded by a team of world-leading scientists, including Luke O’Neill, prof of biochemistry at the School of Biochemistry and Immunology in TCD.
Sotryx said it has assembled a portfolio of products that will address oncology and immunoinflammatory indications through differentiated chemistry approaches, including small molecules, proteolysis targeting chimera and topical formulations.
Immunometabolism is a fast-emerging area of investigation into the role of metabolic pathways in immune cell function. Changes to these pathways are seen as pivotal in the development of a number of severe diseases, including a range of cancer and autoimmune conditions. Correcting immune cell function and/or inhibiting tumour cell growth through immunometabolic therapies has the potential to offer key, complementary and highly differentiated approaches to treating disease.
The Series A funding came from an international syndicate that included SV Health Investors, Sofinnova Partners, Longwood Fund and pharma giant GlaxoSmithKline (GSK)
Mr O’Neill has a longstanding relationship with GSK, having taken a sabbatical to work at the company’s research labs in Stevenage, UK.
“I’m delighted that my sabbatical in GSK has resulted in the formation of this new company in what is a tremendously exciting area,” he said in a statement.